nical specifications; de-identified data were aggregated by CAQH to determine adherence to beta blocker therapy overall, by region, and by type of health plan product. Adherence was defined as claims for at least 75% "days supply" of beta-blocker during a measurement interval. Results: The study population included 15,070 patients from 44 states in 9 CAQH member health plans (45% HMO/POS, 27% Medicare + Choice, 24% PPO, 4% Indemnity). Adherence for 3, 6, 9, and 12 months was 55%, 52%, 49%, and 46%, respectively, across all insurance products and regions. There was a pattern of declining adherence to beta-blockers over time from discharge after MI in all insurance products and all geographic regions. Cumulative national population adherence for HMO/POS products for 3, 6, 9, and 12 months were 57%, 54%, 52%, and 49% respectively. Adherence for Medicare + Choice patients for the same intervals was lower: 49%, 46%, 42%, and 39%. In comparison, 2001 HEDIS data estimated a mean of 92% for prescription of beta-blockers within 7 days of discharge after MI. Conclusion: Despite having prescription and commercial insurance coverage, less than 50% of this large population were still taking beta-blockers one year after MI. In order to capture the survival benefit potentially afforded by beta-blockers, quality improvement initiatives need to focus on longer term outpatient adherence. 11:30 a.m.
Background:
Little is known about patient attitudes towards informed consent and participation in cardiovascular clinical trials (CT). We surveyed 430 consecutive participants in 8 large in-patient (IP) and out-patient (OP) trials between 1998-2002 through a mailed survey twice over 3 months. Results: Of 430 participants, 37 (8.6%) died prior to study completion, and 242 (61.6%) responded to the survey (69% male). Similar proportions had participated in IP and OP CT (46.7% vs. 53.3%). The majority were 50-69 years old (59.8%), with 35.7% >age 69, with no difference in age distribution between genders. The majority had a high school (38.7%) or university degree (28.5%) and were unemployed or retired (66.9%). Most patients had read the study consent form (87.6%), and 3.5% found the consent form too difficult to understand. Women were more likely to feel pressured to join their CT than men (16.2% vs. 5.5%, p=0.024). Side effects attributed to study drug were common among women (27.5% vs. 11.9%, p=0.005), but early drug termination was similar between genders (7.3% vs. 5.6%). The majority f (74.4%) were willing to participate in future CT. Other differences noted:
Conclusions: CT participants are satisfied with informed consent and are willing to participate in future trials.Women are more likely to feel pressured into joining, and to experience study-related side effects. The consent process is sub-optimal for participants of inpatient clinical trials, and warrants further investigation.
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